University Hospital Ulm

Running trials

• Not yet recruiting

  A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination with Fluorouracil, Folinic Acid, and Oxaliplatin (FOLFOX) Compared to Standard of Care in Adult Participants with First-Line Metastatic Pancreatic Ductal Adenocarcinoma

  2025-522563-15-00· Phase 2/3· Source

• Not yet recruiting

  Comparison of Neurocognitive Outcome in Two Standard Regimen for Treatment of Low-risk Medulloblastoma

  NCT07291102· Phase 3· Source

• Not yet recruiting

  Post-intervention dual antiplatelet therapy for mild stroke

  2026-525681-22-00· Phase 3· Source

• Not yet recruiting

  A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma

  NCT07728188· Phase 3· Source

• Recruiting

  SIL204-SL Treatment for Locally Advanced Pancreatic Cancer

  2025-525157-39-00· Phase 2/3· Source

• Not yet recruiting

  An Open-label, DDI Study to Investigate the Effects of Duvakitug on the PK of Selected Cytochrome P450 Substrates

  NCT07923383· Phase 1· Source

• Recruiting

  Cevostamab in Combination With Pomalidomide and Dexamethasone After BCMA- Targeting CAR T-Cell Therapy in Participants With Previously Treated Multiple Myeloma

  NCT07825064· Phase 2· Source

• Recruiting

  Efficacy of Asciminib in Chronic Phase CML Patients With T315I Mutations

  NCT07789574· Phase 2· Source

• Not yet recruiting

  Evaluating the Effects of the EXOPULSE Suit on Mobility, Walking Ability, and Balance in People With Multiple Sclerosis

  NCT07897760· Source

• Recruiting

  A clinical trial to assess the efficacy and safety of ontunisertib compared to placebo in patients with fibrostenosing Crohn’s disease

  2026-525197-19-00· Phase 2· Source

• Recruiting

  Phase 3 Study of Investigator Choice of Chemotherapy with or without Zoldonrasib as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma

  2025-524928-21-00· Phase 3· Source

• Not yet recruiting

  Phase 3 Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC 6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma

  2025-524969-24-00· Phase 3· Source

• Recruiting

  A Phase III, Open-Label, Randomised, Multicentre, Global Study of Adjuvant Datopotamab Deruxtecan in Combination With Rilvegostomig in Participants With High-risk Muscle Invasive Urothelial Carcinoma.

  2025-525030-57-00· Phase 3· Source

• Not yet recruiting

  Continuous or Intermittent Cetuximab Plus FOLFIRI as First-line Treatment in RAS/BRAF Wild-type mCRC Patients

  NCT07004413· Phase 3· Source

• Recruiting

  A clinical trial to learn about the effects of IEV407 when given alone or with endocrine therapy in people with advanced breast cancer

  2025-522707-26-00· Phase 1· Source

• Not yet recruiting

  A Study to Evaluate S241656 Alone or in Combination in Participants With Selected Myeloid Malignancies

  NCT07719348· Phase 1/2· Source

• Recruiting

  Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)

  NCT07711002· Phase 3· Source

• Recruiting

  A Randomized, Double-Blind, Phase 3 Study of Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D–Mutated Metastatic Pancreatic Ductal Adenocarcinoma (DAWN-303)

  2025-525009-18-00· Phase 3· Source

• Not yet recruiting

  AIEOP-BFM ALL 2025 - International collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia

  2025-522190-11-01· Phase 3· Source

• Recruiting

  A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.

  NCT07753993· Phase 3· Source

• Recruiting

  A study to evaluate the efficacy of oxaliplatin- or gemcitabine-based chemotherapy after allocation by standard criteria or by genetic markers in patients with resected pancreatic carcinoma

  NCT05314998· Phase 3· Source

• Recruiting

  A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer

  NCT07673887· Phase 3· Source

• Recruiting

  A Phase 1 Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies

  2026-525234-39-00· Phase 1· Source

• Recruiting

  Registry for Duchenne and Becker Muscular Dystrophy

  NCT07402122· Source

• Recruiting

  Pridopidine Phase 3 Study in Huntington's Disease

  NCT07609108· Phase 3· Source

• Recruiting

  A Randomized Phase 1 / 2 Trial Aiming to Restore UNC13A Function in People living with ALS: FUNCtion ALS

  2025-523111-11-00· Phase 1/2· Source

• Not yet recruiting

  GMMG-HD11/DSMM XXI/64007957MMY3010

  NCT07671287· Phase 3· Source

• Enrolling by invitation

  Long-term Safety and Efficacy of Multiple Long-acting Antibodies Alone and in Combinations for IBD

  NCT07652294· Phase 2· Source

• Recruiting

  A Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination with FOLFOX versus Bevacizumab in Combination with FOLFOX for the First-line Treatment of Metastatic Colorectal Cancer (HARMONi-GI3)

  2025-521587-35-00· Phase 3· Source

• Recruiting

  ToPanc Trial: Survival After Total Versus Partial Pancreaticoduodenectomy for Adenocarcinoma of the Pancreatic Head, Distal Cholangiocarcinoma, and Ampullary Cancer

  NCT06801899· Source

• Recruiting

  PREFer

  NCT06916416· Phase 2· Source

• Recruiting

  A Phase 2 Platform Study to Evaluate Therapies for Inflammatory Bowel Disease

  2025-522001-38-00· Phase 2· Source

• Not yet recruiting

  Phase 2 trial of ARPI to AR-degrader (BMS-986365) switch for suboptimal PSA-response in mCSPC (eARly-SWITCH).

  2025-523672-23-00· Phase 2· Source

• Recruiting

  A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT07577856· Phase 3· Source

• Recruiting

  A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease

  NCT07577843· Phase 3· Source

• Recruiting

  A Substudy of LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis

  NCT07571174· Phase 1· Source

• Recruiting

  Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS (PREVAiLS)

  2025-524002-16-00· Phase 3· Source

• Recruiting

  Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)

  NCT07566156· Phase 3· Source

• Recruiting

  Safety and Clinical Applicability of Transcorneal Electrical Stimulation (TES) in Geographic Atrophy

  NCT07531927· Source

• Recruiting

  A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease

  NCT07483073· Phase 2· Source

• Recruiting

  A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease

  NCT07483099· Phase 2· Source

• Recruiting

  A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety When Given Before Symptoms Appear in Babies With Genetically Diagnosed Spinal Muscular Atrophy (SMA)

  NCT07221669· Phase 3· Source

• Recruiting

  A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)

  NCT07419295· Phase 3· Source

• Recruiting

  A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer

  NCT07365995· Phase 3· Source

• Recruiting

  A Prospective Observational Trial to Assess Treatment Sequences and Factors That Impact Overall Sur-vival in Patients With Chronic Lymphocytic Leukaemia (CLL) Treated Within First-line Studies of the GCLLSG

  NCT06792994· Source

• Recruiting

  Improved Management of Patients With Recent-Onset Stable Chest Pain

  NCT07476040· Source

• Recruiting

  LY4268989 (MORF-057) Co-Administered with Mirikizumab in Adults with Moderately to Severely Active Ulcerative Colitis: A Phase 2 Study

  2025-522338-30-00· Phase 2· Source

• Recruiting

  Cerebral Small Vessel Disease Progression Dependent on Stroke Type

  NCT07611136· Source

• Recruiting

  A Study to Evaluate Efficacy and Safety of MK-8690 in Participants With Moderately to Severely Active Ulcerative Colitis (MK-8690-002)

  NCT07463183· Phase 2· Source

• Recruiting

  A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease

  NCT07326709· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Childhood cancers27 recruiting
• Colorectal cancer18 recruiting
• Pancreatic cancer17 recruiting
• Acute myeloid leukemia16 recruiting
• Chronic lymphocytic leukaemia16 recruiting
• Crohn's disease15 recruiting
• Metastatic breast cancer13 recruiting
• Ulcerative colitis13 recruiting
• Acute lymphoblastic leukaemia12 recruiting
• Liver and biliary tract cancer11 recruiting
• Gastric and esophageal cancer9 recruiting
• Prostate cancer9 recruiting
• Multiple myeloma8 recruiting
• Myelodysplastic syndromes8 recruiting
• ALS (motor neurone disease)7 recruiting
• Bladder cancer7 recruiting
• Macular degeneration7 recruiting
• Ovarian cancer7 recruiting
• Chronic myeloid leukaemia6 recruiting
• Endometrial cancer6 recruiting
• Lung cancer6 recruiting
• Multiple sclerosis6 recruiting
• Diffuse large B-cell lymphoma5 recruiting
• Follicular lymphoma5 recruiting
• Huntington's disease5 recruiting
• Alzheimer disease4 recruiting
• CIDP (chronic inflammatory demyelinating polyneuropathy)4 recruiting
• Mantle cell lymphoma4 recruiting
• Myeloproliferative neoplasms4 recruiting
• Stroke4 recruiting
• Epilepsy3 recruiting
• Head and neck cancer3 recruiting
• High blood pressure3 recruiting
• Hodgkin lymphoma3 recruiting
• Parkinson disease3 recruiting
• Atrial fibrillation2 recruiting
• Chronic kidney disease2 recruiting
• Coronary artery disease2 recruiting
• Kidney cancer2 recruiting
• Melanoma2 recruiting
• Sarcoma2 recruiting
• Triple-negative breast cancer2 recruiting
• Duchenne muscular dystrophy1 recruiting
• Heart failure1 recruiting
• HIV1 recruiting
• Myasthenia gravis1 recruiting
• Neuroblastoma1 recruiting
• Obesity1 recruiting
• Pompe disease1 recruiting
• Spinal muscular atrophy1 recruiting
• Thalassaemia1 recruiting
• Thyroid cancer1 recruiting
• Type 1 diabetes1 recruiting
• Type 2 diabetes1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Recruiting

  A Master Protocol (OLMP): A Study of LY4256984 in Participants With Amyotrophic Lateral Sclerosis (ALS)

  NCT07571200· Phase 1· Source

• Completed

  A clinical trial to learn about the effects of VHB937 in people with Alzheimer's disease

  2024-516966-12-00· Phase 2· Source

• Active, not recruiting

  A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RG6496 in Huntington's Disease

  NCT07246941· Phase 1· Source

• Completed

  A 52-week, Phase 1 Safety, Pharmacokinetic and Pharmacodynamic Study of Siplizumab in Newly Diagnosed Adult Amyotrophic Lateral Sclerosis (ALS) Patients (AURORA)

  NCT06453668· Phase 1· Source

• Active, not recruiting

  A Study to Investigate the Efficacy and Safety of Brivekimig in Adult Participants With Ulcerative Colitis

  NCT06975722· Phase 2· Source

• Completed

  A study to investigate efficacy and safety of SAR441566 in patients with ulcerative colitis

  NCT06867094· Phase 2· Source

• Completed

  A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of BG-60366 in Patients With EGFR-Mutant Non-Small Cell Lung Cancer

  NCT06685718· Phase 1· Source

• Completed

  A Study of Eciskafusp Alfa and Bacillus Calmette-Guérin (BCG) in Participants with High-Risk Bladder Cancer Unresponsive to BCG Treatment

  2024-515410-41-00· Phase 1/2· Source

• Recruiting

  Efficacy and Safety Study of Once-Daily Extended-Release Levetiracetam in Drug-resistant Focal Onset Seizures

  2024-514499-42-00· Phase 3· Source

• Completed

  A study to evaluate S227928 as a Single Agent and in Combination with Venetoclax in Patients with R/R AML, MDS/AML, or CMML

  NCT06563804· Phase 1/2· Source

• Active, not recruiting

  A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

  NCT06291220· Phase 1· Source

• Completed

  Efficacy, Safety and Tolerability of BHV-7000 in Subjects with Idiopathic Generalized Epilepsy with Generalized Tonic-clonic Seizures – SHINE

  NCT06425159· Phase 2/3· Source

• Active, not recruiting

  A Study Assessing Adverse Events and Disease Activity of Intravenously (IV) Infused Telisotuzumab Adizutecan in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer

  NCT06614192· Phase 2· Source

• Completed

  Frequency of Selected Single Nucleotide Polymorphisms in Huntington Disease Gene Expansion Carriers

  NCT06667414· Source

• Active, not recruiting

  Phase IIa Study Evaluating AZD7798 in Crohn's Disease

  NCT06450197· Phase 2· Source

• Completed

  Efficacy and Safety of Rosnilimab in Subjects with Ulcerative Colitis

  2023-508679-34-00· Phase 2· Source

• Recruiting

  Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation

  NCT06252649· Phase 3· Source

• Completed

  Peptide-coupled Red Blood Cells for the Treatment of Multiple Sclerosis

  NCT06430671· Phase 1· Source

• Completed

  A study to investigate the efficacy and safety of luveltamab tazevibulin versus IC chemotherapy in women with ovarian cancer (including fallopian tube or primary peritoneal cancers) expressing FOLR1

  NCT05870748· Phase 2· Source

• Completed

  A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vixarelimab in Participants with Moderate to Severe Ulcerative Colitis

  2023-506655-19-00· Phase 2· Source

• Active, not recruiting

  Iberdomide vs. Iberdomide Plus Isatuximab Maintenance Therapy Post ASCT in Newly Diagnosed Multiple Myeloma

  NCT06216158· Phase 3· Source

• Active, not recruiting

  A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative Colitis

  NCT06257875· Phase 2· Source

• Completed

  A Study of Tobemstomig/RO7247669 Combined with Nab-Paclitaxel Compared with Pembrolizumab Combined with Nab-Paclitaxel in Participants with Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer

  2022-502457-34-00· Phase 2· Source

• Completed

  A Trial to Investigate TransCon TLR7/8 Agonist in Combination with Pembrolizumab, TransCon TLR7/8 Agonist in Combination with TransCon IL-2 β/γ, or Pembrolizumab Monotherapy as Neoadjuvant Therapy in Participants with Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC)

  2023-506092-10-00· Phase 2· Source

• Completed

  Study to Assess Safety and Efficacy of PRI-002 in Patients With MCI to Mild Dementia Due to Alzheimer's Disease (AD)

  NCT06182085· Phase 2· Source

• Withdrawn

  Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHN

  NCT05743270· Phase 2· Source

• Active, not recruiting

  A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment

  NCT06105632· Phase 2· Source

• Terminated

  Continuation Study for Latozinemab

  NCT06111014· Phase 3· Source

• Terminated

  IRI-EXPLORE: A Study to Test Whether BI 765845 Helps People Who Have Had a Heart Attack

  NCT06139328· Phase 2· Source

• Completed

  Randomised, double-blind, placebo-controlled study to assess safety and efficacy of PRI-002 in patients with MCI or mild dementia due to Alzheimer’s disease (AD)

  2022-503148-41-00· Phase 2· Source

• Completed

  A clinical trial to assess the safety and effects of AGMB-129 compared to placebo in patients with fibrostenotic Crohn’s disease.

  2022-502789-26-01· Phase 2· Source

• Active, not recruiting

  A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation

  NCT06045806· Phase 3· Source

• Completed

  EF-39 PANOVA-4: Study of Tumor Treating Fields Concomitant With Atezolizumab, Gemcitabine and Nab-Paclitaxel as First-LineTreatment for Metastatic Pancreatic Ductal Adenocarcinoma

  NCT06390059· Phase 2· Source

• Completed

  STENOVA - A Study to Evaluate Safety, Tolerability, PK and PD of AGMB-129 in Patients With Fibrostenotic Crohn's Disease

  NCT05843578· Phase 2· Source

• Active, not recruiting

  Afimkibart (RO7790121) for the Treatment of Moderate to Severe Active Crohn's Disease

  NCT05910528· Phase 2· Source

• Completed

  Long-term Safety and Efficacy of Efavaleukin Alfa in Subjects With Moderately to Severely Active Ulcerative Colitis

  NCT05672199· Phase 2· Source

• Completed

  Safety and Efficacy of the Olympus CADe System in Real-time Colonoscopy

  NCT05943288· Source

• Completed

  A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma

  NCT05805501· Phase 2· Source

• Completed

  Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma

  NCT05804032· Phase 3· Source

• Completed

  A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Patients with Previously Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma

  2023-505816-39-00· Phase 2· Source

• Completed

  Allogeneic stem cell transplantation vs. conventional therapy as salvage therapy for relapsed / progressed patients with multiple myeloma after first-line therapy (AlloRelapseMMStudy)

  NCT05675319· Phase 3· Source

• Active, not recruiting

  A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE

  NCT05702034· Phase 3· Source

• Completed

  A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Assess the Efficacy, Safety, Tolerability, PK, and Biomarker Effects of PTC857 in Adult Subjects With Amyotrophic Lateral Sclerosis (CARDINALS)

  NCT05349721· Phase 2· Source

• Active, not recruiting

  GENERATION HD2. A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants With Prodromal and Early Manifest Huntington's Disease

  NCT05686551· Phase 2· Source

• Completed

  A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke

  NCT05686070· Phase 3· Source

• Completed

  ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2

  NCT05507216· Phase 3· Source

• Completed

  Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder

  NCT05512377· Phase 2· Source

• Active, not recruiting

  Dose-finding Study of SAR443122 in Adult Participants With Ulcerative Colitis

  NCT05588843· Phase 2· Source

• Completed

  A Study to Evaluate MORF-057 in Adults With Moderately to Severely Active UC

  NCT05611671· Phase 2· Source

• Completed

  A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures

  NCT05614063· Phase 3· Source

Trial sites

• Universitätsklinikum Ulm1 trial
• Department of Cardiology, University Hospital Ulm1 trial
• Department of Cardiothoracic and Vascular Surgery, Ulm University Hospital1 trial
• Department of General and Visceral Surgery, University Hospital Ulm1 trial
• Department of Ophthalmology, University Hospital Ulm1 trial
• Hospital of University of Ulm1 trial
• Ulm University Hospital5 trials
• Ulm University Hospital, Centre for Internal Medicine I0 trials
• Universitaetsklinikum Ulm25 trials
• Universitaetsklinikum Ulm AoeR1 trial
• Universitaetsklinikum Ulm AoR390 trials
• Universitaetsklinikum Ulm /ID# 1352301 trial
• Universitaetsklinikum Ulm /ID# 1484441 trial
• Universitaetsklinikum Ulm /ID# 1530541 trial
• Universitaetsklinikum Ulm /ID# 1649900 trials
• Universitaetsklinikum Ulm /ID# 1649940 trials
• Universitaetsklinikum Ulm /ID# 2035540 trials
• Universitaetsklinikum Ulm /ID# 2154051 trial
• Universitaetsklinikum Ulm /ID# 2234000 trials
• Universitaetsklinikum Ulm /ID# 2301640 trials
• Universitaetsklinikum Ulm /ID# 2442650 trials
• Universitaetsklinikum Ulm /ID# 2537421 trial
• Universitaetsklinikum Ulm /ID# 2577830 trials
• Universitaetsklinikum Ulm /ID# 2586160 trials
• Universitaetsklinikum Ulm /ID# 2624940 trials
• Universitaetsklinikum Ulm /ID# 2631480 trials
• Universitaetsklinikum Ulm /ID# 2669620 trials
• Universitaetsklinikum Ulm /ID# 2696860 trials
• Universitaetsklinikum Ulm /ID# 2734110 trials
• Universitaetsklinikum Ulm /ID# 2800040 trials
• Universitaetsklinikum Ulm /ID# 2838841 trial
• Universitaetsklinikum Ulm /ID# 982021 trial
• Universitaetsklinikum Ulm, Innere Medizin Iii0 trials
• Universitaetsklinikum Ulm (Site 0267)1 trial
• Universitaetsklinikum Ulm. (Site 0402)0 trials
• Universitaetsklinikum Ulm. (Site 0404)0 trials
• Universitaetsklinikum Ulm (Site 0500)1 trial
• Universitaetsklinikum Ulm. (Site 0502)0 trials
• Universitaetsklinikum Ulm. (Site 0530)0 trials
• Universitaetsklinikum Ulm. (Site 0601)0 trials
• Universitaetsklinikum Ulm (Site # 0702)0 trials
• Universitaetsklinikum Ulm. (Site 0902)1 trial
• Universitaetsklinikum Ulm. (Site 0906)1 trial
• Universitaetsklinikum Ulm. (Site 0994)0 trials
• Universitaetsklinikum Ulm. (Site 1106)0 trials
• Universitaetsklinikum Ulm. (Site 1324)0 trials
• Universitaetsklinikum Ulm (Site 2102)1 trial
• Universitaetsklinikum Ulm. (Site 2206)1 trial
• Universitätsklinikum Ulm73 trials
• Universitatsklinikum Ulm AöR13 trials
• Universitatsklinikum Ulm AöR (University of Ulm)1 trial
• Universitätsklinikum Ulm / Augenklinik1 trial
• Universitatsklinikum Ulm, Augenklinik und Poliklinik0 trials
• Universitätsklinikum Ulm, Frauenheilunde und Geburtshilfe0 trials
• Universitätsklinikum Ulm - Innere Med. I0 trials
• Universitätsklinikum Ulm, Institut für Allgemeinmedizin1 trial
• Universitätsklinikum Ulm, Klink für Innere Medizin I1 trial
• Universitätsklinikum Ulm - Leimgrubenweg 12-141 trial
• Universitätsklinikum Ulm - Neurologie0 trials
• Universitätsklinikum Ulm, Universitätsfrauenklinik1 trial
• Universitatsklinikum Ulm (University Hospital Ulm)1 trial
• Universitätsklinikum Ulm, Zentrum für Innere Medizin I1 trial
• Universitatsklinikum Ulm, Zentrum fur Innere Medizin, Innere Medizin III1 trial
• University Hospital of Ulm1 trial
• University Hospital Of Ulm AöR4 trials
• University Hospital of Ulm, Department of Internal Medicine III1 trial
• University Hospital Of Ulm, Universitatsklinikum Ulm2 trials
• University Hospital Ulm12 trials
• University Hospital Ulm -Department of Gynecology1 trial
• University Hospital Ulm, Department of Neurology, Germany1 trial
• University Hospital Ulm, Dept. of Neurology1 trial
• University Hospital Ulm, Otolaryngology & Head and Neck Surgery0 trials

Conditions

Diseases this institution publishes on or runs trials for.

• Acute myeloid leukemia33 works · 31 trials
• Bladder cancer29 works · 13 trials
• Huntington's disease26 works · 11 trials
• ALS (motor neurone disease)18 works · 17 trials
• Head and neck cancer12 works · 16 trials
• Chronic lymphocytic leukaemia8 works · 27 trials
• Frontotemporal dementia7 works · 2 trials